← Back to Explore

Development of Pre-Clinical Assays for Quality Control of Cancer Imaging Agents

ISEF · 2024 Cellular and Molecular Biology

Overview

Glioblastoma is the most aggressive primary brain tumor, with an average survival of 14.6 months even with treatment. Prior research has shown that a protein, PTPµ, is cleaved in tumor tissue, and the abundant fragments allow them to serve as a tumor biomarker. Glioblastoma rapidly proliferates, making it difficult for surgeons to fully resect the tumor. Peptides derived from a short portion of PTPµ’s amino acid sequence are thought to bind to the fragments. By conjugating these peptides to fluorophores, surgeons can better identify what they need to resect. Using two in vitro assays, a bead aggregation assay and a fluorescent bead binding assay, we evaluated the effects of buffer conditions on peptide-protein interactions. Additionally, we sought to identify optimal conditions for peptide binding to PTPµ in hopes of improving clinical imaging agents for glioblastoma resection. With the bead aggregation assay, we found that particular types of media support the best aggregation. There is also a possible effect of pH on aggregation. When moving onto the fluorescent bead binding assay, preliminary research suggests that certain peptides have a strong affinity to PTPµ. Many more buffer conditions and peptides will be tested in future research to determine the conditions under which the peptides have the strongest binding to PTPµ, so they may be used as imaging agents.

Competition history

  • ISEF 2024 Cellular and Molecular Biology · Entry CELL029 · Los Angeles, California, United States

Resources

Related projects

Closest projects by meaning, across every fair and year in the corpus.

Source: Regeneron International Science and Engineering Fair

Save projects to your library

Sign in with Google to keep track of projects you find interesting, organized into folders. Browsing stays public.

Continue with Google